BioLineRx-JHL Biotech Collaborate - Analyst Blog


Shutterstock photo

BioLineRx ( BLRX ) is developing a novel monoclonal antibody, BL-9020, which targets the Natural Killer (NK) receptor NKp46. 

BioLineRx recently joined forces with JHL Biotech for the development and commercialization of BL-9020 for the treatment of type I diabetes. 

As per the deal, JHL Biotech will have global manufacturing rights to BL-9020 along with development and commercialization rights in China and Southeast Asia, while BioLineRx will have development and commercialization rights for the rest of the world. Both the parties will be entitled to single-digit royalties on the sale of BL-9020 in the other party's territory.

We note that in Oct 2013, BioLineRx in-licensed BL-9020 from Yissum Research Development Company of the Hebrew University of Jerusalem, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd.

In China roughly 100 million people are affected by diabetes. By 2035, the number is expected to reach 150 million, thus making China one of the largest diabetes markets in the world. Around 5-10% of diabetes cases are of the type I variant.

Our Take

We are positive on the decision of BioLineRx to collaborate with JHL Biotech. This deal makes sense, as it brings together JHL Biotech's expertise in the development and manufacturing of biologic products and BioLineRx' innovative technologies.

BioLineRx carries a Zacks Rank #3 (Hold). Other better-ranked players in the pharma industry include Sucampo Pharmaceuticals Inc. ( SCMP ), WuXi PharmaTech (Cayman) Inc. ( WX ) and Jazz Pharmaceuticals Inc. ( JAZZ ). All the three stocks carry a Zacks Rank #1 (Strong Buy).

BIOLINE RX LTD (BLRX): Get Free Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

SUCAMPO PHARMAC (SCMP): Free Stock Analysis Report

WUXI PHARMATECH (WX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: BLRX , JAZZ , SCMP , WX

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by